Compare FSM & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSM | SYRE |
|---|---|---|
| Founded | 1990 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 2005 | 2015 |
| Metric | FSM | SYRE |
|---|---|---|
| Price | $9.46 | $47.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $14.00 | ★ $60.13 |
| AVG Volume (30 Days) | ★ 6.3M | 671.6K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.58 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.13 | $10.91 |
| 52 Week High | $13.85 | $49.31 |
| Indicator | FSM | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 40.07 | 67.53 |
| Support Level | $7.77 | $15.01 |
| Resistance Level | $10.16 | N/A |
| Average True Range (ATR) | 0.50 | 2.24 |
| MACD | -0.15 | 0.30 |
| Stochastic Oscillator | 29.31 | 78.80 |
Fortuna Mining Corp is a Canadian-based precious metals mining company with mines in the Latin America and West Africa regions producing gold and silver. It operate mines in Argentina, Burkina Faso, Cote d'voire, Mexico, and Peru. The company's segment consists of Mansfield, Sango, Bateas, Corporate. The company generates the majority of its revenue from Sango segment which operates the Seguela gold mine. Geographically, the company generates the majority of its revenue from Cote d' Ivoire location.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.